IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats

BMC Gastroenterology

Dong Yang⁴  Li-Xia Wang⁴  Chun-Yan Li⁴  Gang Zhao⁴  Ying Zhu³  Zhi-Jun Duan⁴  Xiao-Han Zhai²  Chun-Ye Ma¹  Li-Ping Su⁴  Tian-Yu Zhao⁴ 

[1] Department of Neurology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, Liaoning province, China;Department of Clinical Pharmacology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning province, China;Department of Infectious Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning province, China;Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning province, China

关键词: Apoptosis;    Intestinal barrier;    Tight junction;    IGF-1;    Liver cirrhosis;   

Others  :  1223123
DOI  :  10.1186/s12876-015-0311-5

 received in 2014-11-14, accepted in 2015-06-29,  发布年份 2015

【 摘 要 】

Background

Intestinal barrier dysfunction is not only the consequence of liver cirrhosis, but also an active participant in the development of liver cirrhosis. Previous studies showed that external administration of insulin-like growth factor 1 (IGF-1) improved intestinal barrier function in liver cirrhosis. However, the mechanism of IGF-1 on intestinal barrier in liver cirrhosis is not fully elucidated. The present study aims to investigate the mechanisms of IGF-1 improving intestinal barrier function via regulating tight junctions in intestines.

Methods

We used carbon tetrachloride induced liver cirrhotic rats to investigate the effect of IGF-1 on intestinal claudin-1 and occludin expressions, serum alanine transaminase (ALT) and aspartate transaminase (AST) levels, severity of liver fibrosis, portal pressures, enterocytic apoptosis and lipopolysaccharides (LPS) levels in portal vein. The changes of IGF-1 in serum during the development of rat liver cirrhosis were also evaluated. Additionally, we assessed the effect of IGF-1 on claudin-1 and occludin expressions, changes of transepithelial electrical resistance (TEER) and apoptosis in Caco-2 cells to confirm in vivo findings.

Results

Serum IGF-1 levels were decreased in the development of rat liver cirrhosis, and external administration of IGF-1 restored serum IGF-1 levels. External administration of IGF-1 reduced serum ALT and AST levels, severity of liver fibrosis, LPS levels in portal vein, enterocytic apoptosis and portal pressure in cirrhotic rats. External administration of IGF-1 increased the expressions of claudin-1 and occludin in enterocytes, and attenuated tight junction dysfunction in intestines of cirrhotic rats. LPS decreased TEER in Caco-2 cell monolayer. LPS also decreased claudin-1 and occludin expressions and increased apoptosis in Caco-2 cells. Furthermore, IGF-1 attenuated the effect of LPS on TEER, claudin-1 expression, occludin expression and apoptosis in Caco-2 cells.

Conclusions

Tight junction dysfunction develops during the development of liver cirrhosis, and endotoxemia will develop subsequently. Correspondingly, increased endotoxin in portal system worsens tight junction dysfunction via decreasing intestinal occludin and claudin-1 expressions and increasing enterocytic apoptosis. Endotoxemia and intestinal barrier dysfunction form a vicious circle. External administration of IGF-1 breaks this vicious circle. Improvement of tight junctions might be one possible mechanism of the restoration of intestinal barrier function mediated by IGF-1.

【 授权许可】

   
2015 Zhao et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Benten D, Wiest R: Gut microbiome and intestinal barrier failure-the “Achilles heel” in hepatology? J Hepatol 2012, 56:1221-3.
• [2]Seo YS, Shah VH: The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 2012, 18(4):337-46.
• [3]Garcia-Tsao G, Wiest R: Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18(2):353-72.
• [4]Le Roith D: Insulin-like growth factors. N Engl J Med 1997, 336:633-40.
• [5]Conchillo M, Prieto J, Quiroga J: Insulin-like growth factor I (IGF-I) and liver cirrhosis. Rev Esp Enferm Dig 2007, 99:156-64.
• [6]Lorenzo-Zúñiga V, Rodríguez-Ortigosa CM, Bartolí R, Martínez-Chantar ML, Martínez- Peralta L, Pardo A, et al.: Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006, 55(9):1306-12.
• [7]Hatakeyama N, Kojima T, Iba K, Murata M, Thi MM, Spray DC, et al.: IGF-I regulates tight-junction protein claudin-1 during differentiation of osteoblast-like MC3T3-E1 cells via a MAP-kinase pathway. Cell Tissue Res 2008, 334(2):243-54.
• [8]Huat TJ, Khan AA, Pati S, Mustafa Z, Abdullah JM, Jaafar H: IGF-1 enhances cell proliferation and survival during early differentiation of mesenchymal stem cells to neural progenitor-like cells. BMC Neurosci 2014, 15(1):91. BioMed Central Full Text
• [9]Farhadi A, Banan A, Fields J, Keshavarzian A: Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003, 18:479-97.
• [10]Julio-Pieper M, Bravo JA, Aliaga E, Gotteland M: Review article: intestinal barrier dysfunction and central nervous system disorders - a controversial association. Aliment Pharmacol Ther 2014, 40(10):1187-201.
• [11]Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, et al.: Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012, 42(4):439-46.
• [12]Du Plessis J, Vanheel H, Janssen CE, Roos L, Slavik T, Stivaktas PI, et al.: Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol 2013, 58(6):1125-32.
• [13]Ruan Z, Liu S, Zhou Y, Mi S, Liu G, Wu X, et al.: Chlorogenic acid decreases intestinal permeability and increases expression of intestinal tight junction proteins in weaned rats challenged with LPS. PLoS One 2014., 9(6) Article ID e97815
• [14]Steib CJ, Hartmann AC, v Hesler C, Benesic A, Hennenberg M, Bilzer M, et al.: Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest 2010, 90(7):1024-32.
• [15]Steib CJ, Gerbes AL, Bystron M, Op den Winkel M, Härtl J, Roggel F, et al.: Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol 2007, 47:228-38.
• [16]Yokoyama Y, Xu H, Kresge N, Keller S, Sarmadi AH, Baveja R, et al.: Role of thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol 2003, 284:G453-60.
• [17]Khoshnood A, Nasiri Toosi M, Faravash MJ, Esteghamati A, Froutan H, Ghofrani H, et al.: A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis. Hepat Mon 2013., 13(2) Article ID e6181
• [18]Rehem RN, El-Shikh WM: Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 2011, 58(107–108):949-54.
• [19]Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y: Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 2008, 49(1):34-42.
• [20]Assy N, Hochberg Z, Amit T, Shen-Orr Z, Enat R, Baruch Y: Growth hormone stimulated insulin-like growth factor (IGF-1) and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997, 27:796-802.
• [21]Chang TC, Lin JJ, Yu SC, Chang TJ: Absence of growth hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology 1990, 11:123-6.
• [22]Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989, 10:68-91.
• [23]Bonefeld K, Møller S: Insulin-like growth factor-I and the liver. Liver Int 2011, 31(7):911-9.
• [24]Thomsen KL, Nielsen SS, Grønbiek H, Flyvbjerg A, Vilstrup H: Effects of lipopolysaccharide endotoxin on the insulin-like growth factor I system in rats with cirrhosis. In Vivo 2008, 22(6):655-61.
• [25]Priego T, Granado M, Ibanez dC I, Martin AI, Villanua MA, Lopez-Calderon A: Endotoxin at low doses stimulates pituitary GH whereas it decreases IGF-I and IGF-binding protein-3 in rats. J Endocrinol 2003, 179:107-17.
• [26]Defalque D, Brandt N, Ketelslegers JM, Thissen JP: GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am J Physiol 1999, 276:E565-72.
• [27]Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, Pañeda A, et al.: Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading tocirrhosis reversion in rats. Hepatology 2010, 51(3):912-21.
• [28]Cantürk NZ, Cantürk Z, Ozden M, Dalçik H, Yardimoglu M, Tülübas F: Protective effect of IGF-1 on experimental liver cirrhosis-induced common bile duct ligation. Hepatogastroenterology 2003, 50(54):2061-6.
• [29]Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, et al.: Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 1997, 113(5):1682-91.
• [30]Toda K, Kumagai N, Tsuchimoto K, Inagaki H, Suzuki T, Oishi T, et al.: Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis. J Gastroenterol 2000, 35(3):214-20.
• [31]Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-69.